PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 58 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $17,000 | -73.4% | 95,763 | -10.3% | 0.00% | – |
| Q2 2022 | $64,000 | -65.6% | 106,766 | -24.2% | 0.00% | – |
| Q1 2022 | $186,000 | -73.7% | 140,868 | -48.1% | 0.00% | – |
| Q4 2021 | $708,000 | +52.6% | 271,277 | +81.9% | 0.00% | – |
| Q3 2021 | $464,000 | -3.3% | 149,162 | +15.6% | 0.00% | – |
| Q2 2021 | $480,000 | +41.2% | 129,081 | +31.1% | 0.00% | – |
| Q1 2021 | $340,000 | -6.8% | 98,461 | -9.2% | 0.00% | – |
| Q4 2020 | $365,000 | +2.5% | 108,449 | +6.7% | 0.00% | – |
| Q3 2020 | $356,000 | -52.1% | 101,650 | -37.1% | 0.00% | – |
| Q2 2020 | $743,000 | +161.6% | 161,676 | +88.8% | 0.00% | – |
| Q1 2020 | $284,000 | -54.7% | 85,623 | -16.5% | 0.00% | – |
| Q4 2019 | $627,000 | -0.6% | 102,584 | -32.3% | 0.00% | – |
| Q3 2019 | $631,000 | -42.8% | 151,454 | +79.9% | 0.00% | – |
| Q2 2019 | $1,104,000 | +5157.1% | 84,194 | +3673.8% | 0.00% | – |
| Q1 2019 | $21,000 | – | 2,231 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Johnson & Johnson Innovation - JJDC, Inc. | 1,607,044 | $5,400,000 | 0.70% |
| NEA Management Company, LLC | 6,643,704 | $22,323,000 | 0.59% |
| DAFNA Capital Management LLC | 320,542 | $1,077,000 | 0.32% |
| Platform Technology Partners | 141,025 | $474,000 | 0.23% |
| Parkman Healthcare Partners LLC | 110,547 | $371,000 | 0.10% |
| Rock Springs Capital Management LP | 1,314,374 | $4,416,000 | 0.09% |
| GSA CAPITAL PARTNERS LLP | 140,341 | $472,000 | 0.08% |
| SABBY MANAGEMENT, LLC | 65,000 | $218,000 | 0.04% |
| Virtu Financial LLC | 28,821 | $97,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 127,600 | $429,000 | 0.01% |